pfizer glp-1 drug Is on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? Safety worries spur Pfizer to
Description
Noticing hair thinning during GLP-1 weight loss
A Breakthrough Award, New Evidence in Parkinson's and Heart Disease
Background: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk
GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy
Primary outcomes included changes in TTR, INR, and INR recheck frequency
Wondering about GLP-1 dosing approaches
